NY-IFF
22.5.2023 12:56:26 CEST | Business Wire | Press release
IFF (NYSE:IFF) today released its 2022 Do More Good Report, which highlights performance and progress against goals set forth in the Do More Good Plan, the Company’s environmental, social, governance, plus sustainable solutions (or ESG+) strategy and roadmap that activates its purpose of applying science and creativity for a better world.
The Do More Good Report: IFF’s 2022 ESG+ Progress, describes the first full year of performance and progress as One IFF following the 2021 merger with DuPont’s Nutrition & Biosciences division. IFF will hold a live webcast to discuss the Company’s Do More Good Plan and goals, 2022 ESG+ results, and 2023 sustainability outlook on May 23, 2023, at 9:00 a.m. ET.
“When we launched our Do What Matters Most strategy in 2022, we committed to embedding ESG+ in all we do,” said Frank Clyburn, IFF CEO. “Our 2022 Do More Good Report illustrates the steps we’re taking to deliver on our commitments to address sustainable development imperatives. Our world-class R&D program and commitment to innovation fuels a pipeline of exciting sustainable solutions that are helping our customers reach their ESG goals and, in turn, responding to heightened consumer expectations on sustainability.”
The 2022 Do More Good Report is organized according to the four pillars of the Do More Good Plan, which reflect the areas where the Company can have the greatest positive impact in addressing the world’s most pressing sustainable development challenges: Sustainable Solutions; Climate & Planetary Health; Equity & Wellbeing; and Transparency & Accountability.
2022 performance highlights and achievements by IFF include:
- Recognized externally for ESG leadership, including being named to the Dow Jones Sustainability Indices for the third consecutive time, and maintaining the 2022 EcoVadis platinum sustainability rating, placing IFF among the top 1% of companies assessed;
- Enabled customers and consumers to save more CO2e than generated at IFF’s own manufacturing sites by accelerating the wider adoption of sustainable solutions in the marketplace, as documented by life cycle assessments;
- Named to the CDP Climate A list for the eighth consecutive year and completed its first virtual power purchase agreement, expected to cover approximately 30% of the total electricity needs of its European sites when it becomes operational at full capacity in 2024;
- Recertified as EDGE Move level globally for its commitment to gender parity, and included in the Bloomberg Gender-Equality Index for the second time;
- Introduced a Global Parental Leave Policy that grants a minimum of 16 weeks of 100% paid leave for a new IFF parent, regardless of gender identity or expression;
- Linked ESG performance metrics for reduction of greenhouse emissions and increases in company-wide gender representation to the Annual Incentive Plan Award for executive leaders, impacting 2022 variable compensation by 5%;
- Completed updates to its Code of Conduct training and certification campaign, achieving a 99.8% acknowledgment rate among employees.
To learn more, visit iff.com/responsibilities and use #DoMoreGoodxIFF to follow the conversation on its social channels.
Webcast
IFF will hold a live webcast to discuss the Company’s Do More Good Plan, 2022 key performance metrics, progress against 2030 goals and 2023 outlook on May 23, 2023 at 9:00 a.m. ET., where Mr. Clyburn will be joined by Michael DeVeau, Senior Vice President, Corporate Finance and Investor Relations; Dr. Greg Yep, Chief Research & Development, Global Integrated Solutions and Sustainability Officer; Ralf Finzel, Chief Operations Officer; Deborah Borg, Chief Human Resources, Diversity, Equity & Inclusion and Communications Officer; and Jennifer Johnson, General Counsel and Corporate Secretary. The webcast and accompanying slide presentation may be accessed on the Company’s Investor Relations website at ir.iff.com.
IFF invites investors, analysts and all IFF stakeholders to participate by phone by calling 1-404-975-4839 from the United States and toll-free from other locations by calling +1-833-470-1428. The access code for the conference call is 758853, and a listen-only webcast will be available at ir.iff.com. For those unable to listen to the live webcast, IFF will post a recorded version on the Company’s website approximately one hour after the event.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom